Hair loss—specifically androgenetic alopecia or pattern hair loss—affects an estimated 80 million people in the United States. Despite how common this condition is, the medical community hasn’t seen a new FDA-approved prescription pill for pattern hair loss in nearly 30 years.
That drought is finally ending. A highly anticipated investigational medication known as VDPHL01 is currently making waves in the dermatology world. Here is a clear breakdown of this promising new treatment, how it works, what to expect regarding safety and costs, and what it means for the future of hair restoration.
What is VDPHL01?
VDPHL01 is a daily oral medication currently in late-stage Phase 3 clinical trials. Developed by the biopharmaceutical company Veradermics, VDPHL01 is a completely non-hormonal pill designed specifically to treat pattern hair loss.
The active ingredient is minoxidil, the exact same proven hair-growth agent found in popular over-the-counter topical treatments. However, VDPHL01 is uniquely engineered as an extended-release tablet. This entirely changes how your body processes the medication.
The Problem with Current Hair Loss Treatments
To understand why a dermatologist for hair loss might get excited about VDPHL01, look at the massive limitations of today’s standard treatments. Right now, patients are forced to choose between messy routines and potential side effects.
- Topical Minoxidil: While effective for a lot of people, topical foams and serums are greasy, can cause severe scalp irritation, and ruin daily hairstyles. Because of the daily hassle, studies show up to 86% of patients quit using topical minoxidil within their first year.
- Immediate-Release Oral Minoxidil: To avoid messy foams, dermatologists frequently prescribe generic oral minoxidil “off-label.” The problem is this immediate-release pill was originally created decades ago to treat severe high blood pressure. When you swallow it, the medication floods your bloodstream all at once. This rapid spike can trigger cardiovascular side effects like a racing heartbeat, dizziness, or fluid retention.
The “Gel Matrix” Breakthrough
VDPHL01 fixes the problems of standard pills by using a proprietary extended-release “gel matrix” technology.
Instead of dumping the medication into your system all at once, the tablet dissolves gradually in your stomach. This ensures a slow, steady drip of minoxidil into the bloodstream over a 24-hour period.
This mechanism does two vital things:
- Protects the Heart: It blunts the massive spike of medication, keeping the drug concentration safely below the threshold that triggers cardiac side effects.
- Maximizes Hair Growth: Hair follicles are stubborn. They need constant stimulation to stay in their active growth phase. VDPHL01 sustains the medication in the body for twice as long as standard pills, giving your hair exactly what it needs to grow thicker and faster.
2026 Clinical Trial Results
The clinical data for VDPHL01 has been incredibly strong. In April 2026, Veradermics released results from their major Phase 2/3 clinical trial (Study 302), involving over 500 men with mild-to-moderate pattern hair loss.
After six months of treatment, the numbers spoke for themselves:
- Massive Hair Regrowth: Patients taking the drug saw a rapid average increase of 30.3 to 33.0 thick, healthy hairs per square centimeter, compared to just 7.3 hairs for the placebo group.
- Fast Results: Doctors noted statistically significant improvements in hair growth as early as month two.
- High Patient Satisfaction: Nearly 86% of patients taking VDPHL01 twice daily reported noticeable improvements in their hair coverage.
Understanding the Safety Profile of VDPHL01
Because VDPHL01 is a systemic medication—meaning it travels through your whole body, not just your scalp—understanding its safety profile is incredibly important.
Safety for Men and Women
In the recent Phase 2/3 trials for men, VDPHL01 was exceptionally well-tolerated. Out of hundreds of patients, there were zero treatment-related serious adverse events and zero cardiac issues of special interest.
For women, traditional oral hair loss medications (like finasteride and dutasteride) carry high risks because they alter hormones and can cause severe birth defects in male fetuses. Because VDPHL01 is entirely non-hormonal, it avoids these specific feminization risks. It is currently undergoing a dedicated 500-patient clinical trial (Study 306) to confirm its safety and efficacy for female pattern hair loss.
Pregnancy and Women of Childbearing Age
While non-hormonal, VDPHL01 is a powerful vasodilator. It is strictly contraindicated during pregnancy and breastfeeding. Women of childbearing age must have a negative pregnancy test before starting the medication and are required to use highly effective contraception for the entire duration of the treatment, plus one month after stopping.
Contraindications
VDPHL01 is not for everyone. You should not take this medication if you have a history of:
- Heart failure or a recent heart attack.
- Pericardial effusion (fluid buildup around the heart) or pericarditis.
- Pheochromocytoma (a rare tumor of the adrenal glands).
- Severe kidney disease or renal impairment.
Possible Drug Interactions
Because minoxidil was originally a blood pressure drug, taking VDPHL01 with other medications can cause dangerous drops in blood pressure. You must tell your doctor if you take:
- Other antihypertensive medications (blood pressure pills) or diuretics.
- Vasodilators used for erectile dysfunction (such as Viagra or Cialis).
- High amounts of alcohol, which can compound the blood-pressure-lowering effects and lead to fainting.
Required Blood Work and Baseline Tests
Before prescribing VDPHL01, your dermatologist will require a medical evaluation to ensure your body can safely process the drug. Standard baseline testing includes:
- Blood Pressure and Heart Rate Check: To establish your normal resting baseline.
- Renal Function Blood Test: A basic metabolic panel to check your kidneys, as they are responsible for filtering the medication out of your body.
- Electrocardiogram (ECG): If you have any personal or family history of cardiac issues, your doctor may request an ECG to check your heart rhythm.
- Pregnancy Test: Required for all female patients of childbearing potential.
Projected Costs for VDPHL01
Because VDPHL01 is still finishing clinical trials, an exact retail price hasn’t been set by Veradermics. However, we can make an educated estimate.
Generic immediate-release oral minoxidil is cheap (often $10 to $30 a month) because it is an older, off-patent drug. VDPHL01 relies on newly patented extended-release technology.
Patients can expect VDPHL01 to be priced as a premium, branded medication. Industry estimates suggest a cash price ranging between $75 to $150 per month. Most health insurance plans classify hair loss treatments as cosmetic, meaning patients will likely pay out-of-pocket, though the manufacturer will likely offer patient savings cards to lower the monthly cost upon release.
VDPHL01: Frequently Asked Questions
1. Do I need a prescription to get VDPHL01?
Yes. Unlike over-the-counter topical foams, VDPHL01 is a systemic oral medication. Once it is fully approved, you will need a prescription and routine monitoring from a licensed healthcare provider.
2. How is this different from Rogaine?
Rogaine is a brand name for topical minoxidil, which you apply directly to your scalp. It is messy and hard to stick with daily. VDPHL01 uses the exact same active ingredient but delivers it internally through a slow-release pill, eliminating the mess while providing steady stimulation to the hair follicles via your bloodstream.
3. Will I experience a “dread shed” when starting VDPHL01?
It is very likely. Any effective minoxidil treatment speeds up the hair follicle’s life cycle. This pushes out older, resting hairs to make way for new, thicker hairs. If you experience increased shedding during the first few weeks, it is a great sign that the medication is working.
4. Can I stop taking it once my hair grows back?
No. Pattern hair loss is a chronic, progressive condition. Just like with topical treatments, VDPHL01 only works as long as you take it. If you stop the medication, your hair follicles will revert to their previous state, and you will lose the new hair you gained within a few months.
5. Does it cause unwanted hair growth on the face or body?
Hypertrichosis (increased body hair) is a known side effect of oral minoxidil. Because VDPHL01 travels through the bloodstream, some patients may notice slightly increased hair growth on their arms, face, or back. However, the extended-release formula aims to minimize these systemic side effects compared to traditional fast-acting pills.
6. When will VDPHL01 be available at my clinic?
The drug is currently wrapping up its final Phase 3 clinical trials, with more data expected in late 2026. Following these trials, Veradermics will submit their application to the FDA. If all goes smoothly, we could see VDPHL01 hit pharmacy shelves sometime in late 2027 or early 2028.
Ready to Reclaim Your Hair?
You don’t have to wait until 2028 to start fighting back against hair thinning. Derma clinic offers the most advanced, evidence-based hair restoration treatments available right now. Contact Derma Clinic to schedule a comprehensive hair loss consultation and build a personalized treatment plan designed just for you.